focus
Can unicorns survive without data? Did biotech get over its skis? And what is going on at Biogen?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde Therapeutics, billed as “Moderna 2.0,” ran into behind-the-scenes problems with its scientific data. We also discuss how Biogen’s boardroom scandal has roiled a company that was supposed to be entering a new era.
advertisement
For more on what we cover, here’s the Laronde story; here’s the latest on Biogen; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.
Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Next article： Hepatitis C has a cure — but many Americans still lack access to it
